Healio Gastroenterology | May 6, 2020 A novel, blood-based assay improved the detection of advanced and non-advanced adenomas by analyzing cell-free DNA and circulating gastrointestinal epithelial cells, according to research from Digestive Disease Week.
Becker’s Hospital Review | May 04, 2020 CellMax Life released results from its U.S. study of the FirstSight blood test that revealed the test detected colorectal cancer with 100 percent sensitivity at 90 percent specificity.
BIOCENTURY | JAN 18, 2018
CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected colorectal cancer with 84% sensitivity and 97.3% specificity. The single-site, Taiwanese trial enrolled 620 adults who were undergoing a routine colonoscopy or who had adenomatous polyps or early to late-stage colorectal cancer.
HealthNewsDigest | Jan 20, 2019
According to the American Society for Gastrointestinal Endoscopy, colorectal cancer (aka colon cancer) is the second leading cause of cancer-related deaths in the United States (when men and women are combined). It is the third leading cause of cancer-related deaths when men and women are considered separately (behind lung and prostate cancer in men, and behind lung and breast cancer in women). The disease causes more than 50,000 deaths annually in the US.
NEW YORK (GenomeWeb) – JAN 02, 2019
As part of the open-label, multicenter, single arm clinical trial, the team plans to enroll patients with stage II and III colorectal cancer that has separately been surgically resected or in addition to being treated with chemotherapy.
The partners will start the Phase I trial later this year with patients who test positive on the CMx test to receive the natural killer cell therapy treatment. The firms have designed the trial to track patients’ cancer status multiple times during treatment, using the CMx blood test to determine treatment response.
CellMax’s blood test isolates and analyzes both CTCs and cell-free DNA from a sample of blood to detect six types of analytes, including four classes of genomic mutations, microsatellite instability, and CTCs.
“Colorectal cancer is the second deadliest cancer in the US with 150,000 new cases and $14 billion spent on treatment annually,” CellMax Cofounder and CEO Atul Sharan said in a statement. “Medigen’s vision to develop innovative cancer therapies especially for the earlier stages of cancer when it is most treatable, is very much aligned to CellMax Life’s mission not reduce mortality from colorectal cancer.”
Financial details of the agreement were not disclosed.
“Because we expect to recruit patients with early-stage cancer, test sensitivity was the key criteria for platform selection,” Medigen Chairman and CEO Stanley Chang said in a statement. “By combining the CMx assay with the CellMax ct-DNA liquid biopsy … we hope to have the most sensitive test for treatment selection and monitoring response.”
